Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:affiliatedWith |
gptkb:ABC_University
gptkb:DEF_Research_Center |
| gptkbp:campusFacilities |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:chemicalFormula |
C20H24N2O2
contains thiazole ring phenylthiazole contains_benzothiazole_moiety contains_dimethylamino_group benzothiazole_derivative |
| gptkbp:clinicalTrials |
gptkb:United_States
Europe Phase II randomized controlled trial safety profile established efficacy demonstrated |
| gptkbp:compatibleWith |
high
|
| gptkbp:competitors |
high
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:consequences |
headache
weight gain sexual dysfunction |
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:drugInterdiction |
IND-123456
|
| gptkbp:enrollment |
adults
|
| gptkbp:fauna |
rat model
mouse_model |
| gptkbp:future_plans |
clinical trials
combination therapy studies long-term effects study |
| https://www.w3.org/2000/01/rdf-schema#label |
WME-767
|
| gptkbp:impact |
nausea
insomnia dry mouth |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not yet available
|
| gptkbp:origin |
(2S)-2-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)-1-(4-fluorophenyl)ethyl)-1,3-benzothiazole
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
gptkb:Pharmacology_Biochemistry_and_Behavior
gptkb:Clinical_Pharmacology_&_Therapeutics gptkb:European_Journal_of_Pharmacology Journal of Medicinal Chemistry |
| gptkbp:regulatoryCompliance |
under investigation
|
| gptkbp:related_to |
WME-765
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research_areas |
neurology
psychiatry |
| gptkbp:research_focus |
neuropharmacology
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:sponsor |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:targets |
D2 receptor
5-HT receptor Dopamine receptor |
| gptkbp:triggerType |
serotonin reuptake inhibitor
|
| gptkbp:uses |
antidepressant
|
| gptkbp:weight |
324.42 g/mol
|